Orion Pharma Limited announced consolidated unaudited earnings results for the third quarter and nine months ended March 2017. For the quarter, the company reported consolidated EPS was BDT 0.56 for January-March 2017 as against BDT 0.33 for January-March 2016. For the nine months, the company reported consolidated EPS was BDT 3.02 for July 2016-March 2017 as against BDT 2.33 for July 2015-March 2016. Consolidated NOCFPS was BDT 8.54 for July 2016-March 2017 as against BDT 10.23 for July 2015-March 2016. Consolidated NAV per share (including and excluding Revaluation Surplus) was BDT 71.14 and BDT 62.63 respectively as on March 31, 2017 and BDT 69.99 and BDT 61.34 respectively as on June 30, 2016.